Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Lantern Pharma outlines $15B-$20B market potential as AI-driven pipeline advances and funding needs intensify (NASDAQ:LTRN)
Management warns of a need for substantial additional funding to continue operations beyond late July to mid-September 2026; advancing clinical trials and commercial initiatives depends on securing new financing. Lantern Pharma positions its…
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan'), a pharmaceutical technology company focusing on developing innovative drug delivery platform…
MTIP invests in pharma regulatory compliance provider Verifarma
A verification email is on its way to you. Please check your spam or junk folder just in case. If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email:.
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN
Hennion & Walsh Asset Management Inc. increased its holdings in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 148.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The…
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO
Assenagon Asset Management S.A. trimmed its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 87.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund…
Tempus AI: An Attractive Entry Point At Current Prices (NASDAQ:TEM)
Tempus AI is rated Strong Buy with a $71 12-month price target, reflecting 67% upside after a 60% share price decline. TEM's integrated genomic and clinical data flywheel creates a defensible moat, reinforced by the Ambry Genetics acquisition and…
Dr Reddy's agrees to change 'Olymviq' to 'Olymra', ends dispute with maker of similar-sounding 'Ozempic'
Danish pharma giant Novo Nordisk and Indian generic drugmaker Dr Reddy's Laboratories (DRL) have put an end to their trademark dispute over Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic. DRL has agreed that they will henceforth…
These are Barclays' top defensive stocks. They also pay solid dividends
Investors looking to navigate the choppy market should consider certain defensive plays, according to Barclays. That's because it's become clear that geopolitics, oil, artificial intelligence disruption and private credit are no longer just side…
Air Canada's CEO Will Resign After Making One Critical Mistake Following a Fatal Crash
A two-minute condolence video cost Air Canada's CEO his job. Michael Rousseau announced Monday by the end of the third quarter, days after releasing a statement about a fatal runway collision that was delivered almost entirely in English. He said…
India Should Build Coalitions To Defend Consensus-Based Decision-Making at WTO: Interview
Chennai: The WTO's 14th Ministerial Conference (MC14) held in Cameroon ended without agreement on key issues, including e-commerce moratorium and expiry of safeguards against non-violation complaints against intellectual property policies. MC14 was…
CAG Flags Irregularities by TSIIC in Land Allotment
Hyderabad: The Comptroller and Auditor General of India (CAG) has flagged serious irregularities in land allotment and acquisition practices of the Telangana Industrial Infrastructure Corporation Limited (TSIIC) during the previous BRS regime…
Bristol Myers Squibb adding 3 medications on TrumpRx
EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton…
Over-the-top psychedelic promos could undermine the field's drug development efforts
“One company may have figured out how to actually rewire the brain with 100% patient improvement in Phase 2 trials. And FDA may have just handed them a golden ticket,” a voice intoned on a YouTube video about a biotech called Helus…
Scott Bessent Deploys the Power of the Treasury to Stop Health Care Fraud: 'We Are All Hands on Deck
This is why Secretary of the Treasury Scott Bessent may well go down as the greatest Treasury Secretary of our lifetimes. Unlike the majority who have served in this cabinet position, Bessent is neither a figurehead nor there to maintain the status…
'Going into industry' is still a dirty phrase for academia. We need to change this
Raised eyebrows. Strained smiles. Murmurs of reluctant congratulations. These are just some of the responses I received from lab colleagues when I told them I was leaving academia for a commercially-driven career — or, less elegantly…
Receive a Daily briefing on Pharma Industry News
Get Started